



NEWS RELEASE

# JANSSEN PRESENTS LONG TERM PHASE 3 EFFICACY AND SAFETY DATA OF SIRUKUMAB IN RHEUMATOID ARTHRITIS PATIENTS WHO HAD AN INADEQUATE RESPONSE AND/OR WHO WERE INTOLERANT TO ANTI-TNFs

6/14/2017